The effect of SolcoUrovac® for the treatment of pre-operative urinary tract infections and for the prevention of post-operative infections of this type was investigated in an open, comparative study in two groups, each consisting of 14 patients in whom a hysterectomy was planned. The aim of this new preparation is to produce an immunostimulation leading to an increased secretion of secretory IgA (slgA) antibodies in the urinary tract and thus to a defence against infection. Fourteen patients with existing bacterial urinary tract infections were cured by use of the preparation before the operation. Fourteen other patients without bacteriuria were not treated and served as controls. After the operation a urinary tract infection occurred in 2 of the treated patients and in 4 of the 14 control patients. In the patients treated with immunotherapy urine slgA increased significantly, on average from 2 to 5.7 mg/g creatinine, while in the control group the values remained constant.

Keywords:
Urinary tract infections, Therapy, Prophylaxis, Immunisations, Urine slgA, SolcoUrovac
This content is only available via PDF.
© 1987 S. Karger AG, Basel
1987
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.